Duke Health explicitly includes low-dose antidepressants among its menopause treatment options. For a reader seeking help with hot flashes, the useful first question is what symptom the proposed medicine is intended to address. The drug family’s familiar name should not replace that explanation or become a diagnosis in its own right.
This review was completed September 29, 2026. It considers Duke’s documented care, the distinction between a symptom goal and a treatment family, and the responsibilities left unresolved by a public overview. It does not identify a particular Duke prescription, recommend an amount or claim an observed treatment result.
Start with the problem that is interrupting daily life
Duke’s menopause page invites discussion of hot flashes, sleep problems and other concerns, and describes an assessment before treatment selection. That provides a clinical setting in which a symptom can be examined instead of immediately assigned a medicine. A report of disrupted sleep, for example, does not itself establish the cause.
The visit-goals guide helps separate what the person wants to improve from the intervention ultimately chosen. For this review, the relevant finding is that Duke offers assessment and names nonhormonal care. It is not a promise that a particular symptom pattern qualifies a reader for a prescription, nor evidence that everyone with a similar complaint receives the same approach.
The antidepressant category is published, but the exact medicine is not
Duke’s treatment description says some antidepressants may help hot flashes, night sweats and sleep disturbance. It discusses this nonhormonal option in relation to people who may not be good candidates for hormone therapy. The page does not identify a selected drug or explain an individual prescribing decision.
The medicine-family guide distinguishes such categories from exact products. The term antidepressant should not be read as Duke diagnosing depression in everyone receiving one for a menopause-related goal. Conversely, its appearance does not establish that mood, sleep and hot flashes would all improve together. The clinician’s explanation needs to connect the actual proposed medicine with the particular reason for considering it.
Evidence for a family does not approve every member for the same purpose
The 2023 Menopause Society position-statement abstract lists certain antidepressant families among evidence-supported approaches for vasomotor symptoms. That professional evidence review is not a regulatory approval for every medicine in those families. It also predates later product developments and should not be treated as an exhaustive current catalog.
The FDA’s current treatment overview describes multiple approved nonhormonal therapies. Neither source identifies what Duke would prescribe. Cleveland Clinic’s review examines another service that discusses hot-flash medicines without naming the selected product. Keeping the evidence level and the product level separate prevents a broad family description from becoming more specific than the provider’s record.
An evaluation may find a different explanation for the complaint
Duke’s assessment section mentions conditions such as hypothyroidism, untreated depression and anxiety that can resemble menopause-related symptoms. It also describes considering relevant health risks and other conditions. This is a reason to preserve the assessment step, not a tool for readers to decide which diagnosis they have.
An unresolved symptom can have implications for the treatment goal. A plan addressing hot flashes is not automatically a plan addressing every cause of poor sleep or changes in mood. The Mayo review considers a service with several distinct consultation goals. Neither institution’s scope permits this publication to assign a cause or select a medicine from a list of symptoms.
Nonhormonal does not remove medication-specific responsibilities
The FDA’s fezolinetant safety communication illustrates why a medicine without hormones still needs its own safety explanation: that product has a serious liver-injury risk and requires liver testing. This is separate regulatory context, not evidence that Duke offers or would select fezolinetant.
The liver-monitoring context guide should not be used as a personal testing schedule. The exact drug would determine which warnings, interactions and follow-up obligations need discussion. Duke’s antidepressant category does not share one universal safety plan with every other nonhormonal family. The review therefore asks who explains and follows the selected medicine rather than assuming that avoiding hormones eliminates clinical responsibilities.
Regional care and the complete financial arrangement need confirmation
Duke’s service information describes locations throughout North Carolina’s Triangle and provides an appointment pathway. It is a clinical service description, not an unrestricted national online-drug offer. The relevant practice would need to confirm appointment conditions and whether its care is available to the person seeking it.
The page does not establish a total covering a selected visit, further assessment and a particular medication. A quotation for one component cannot complete the others. This review has not verified insurance benefits, laboratory charges, pharmacy availability or renewal arrangements. Those questions matter to a sustainable plan, but their answers cannot be calculated from the name of a treatment family or the institution’s general description of care.
A useful comparison preserves the aim and the unresolved prescription
Duke’s published offer supports discussing low-dose antidepressants as one nonhormonal family within menopause care. It leaves the exact product, intended individual benefit and practical follow-up open. A comparison should retain both the documented option and those limits.
The service’s scope is broader than a hot-flash prescription, but breadth alone does not demonstrate a better result. A future explanation should make clear what improvement is sought, what medicine or support is proposed and how benefit and problems would be reviewed. This assessment supplies no regimen, patient rating or firsthand clinical endorsement. Its value is a more precise starting question, with the actual treatment choice remaining part of professional care.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Duke Health — MenopauseOfficial clinical service description, accessed September 29, 2026; an individual prescription, access arrangement, full price and outcome are not established. Published treatment categories are not an all-product formulary. · Checked 2026-09-29
- The 2023 nonhormone therapy position statement of The North American Menopause Society — PubMed abstractPrimary professional position-statement abstract, published 2023; vasomotor-symptom scope only. Full article not retrieved. Predates later drug approvals; does not evaluate these clinics or equate all forms of counseling. · Checked 2026-09-29
- FDA — Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsCurrent federal consumer overview, accessed September 29, 2026; confirms multiple approved nonhormonal therapies. Not a clinic’s formulary, a treatment protocol or proof all requested hormone-label changes are completed. · Checked 2026-09-29
- FDA — Fezolinetant serious liver-injury safety communicationFederal primary safety communication; the retrieved text displays the September 12, 2024 communication. Used for serious liver-risk and testing context only; current boxed warning and contraindications are separately supported by the current exact DailyMed label where discussed. · Checked 2026-09-29